Preferred Label : hydroxamic acids;
MeSH definition : A class of weak acids with the general formula R-CONHOH.;
MeSH synonym : acids, hydroxamic; hydroxamic acid; acid, hydroxamic;
Wikipedia link : https://en.wikipedia.org/wiki/Hydroxamic acid;
Is substance : O;
Origin ID : D006877;
UMLS CUI : C0020314;
- Allowable qualifiers
- Currated CISMeF NLP mapping
- Indexing information
- Record concept(s)
- Related MeSH Supplementary Concept(s)
- ABS 130 [MeSH Supplementary Concept]
- ABT-770 [MeSH Supplementary Concept]
- BB 2116 [MeSH Supplementary Concept]
- BB 2275 [MeSH Supplementary Concept]
- BB 2284 [MeSH Supplementary Concept]
- BB 3103 [MeSH Supplementary Concept]
- BB 3644 [MeSH Supplementary Concept]
- BB3497 [MeSH Supplementary Concept]
- BJB432 [MeSH Supplementary Concept]
- BL1521 [MeSH Supplementary Concept]
- BML-281 [MeSH Supplementary Concept]
- CG 0006 [MeSH Supplementary Concept]
- CH6631 [MeSH Supplementary Concept]
- CT 1418 [MeSH Supplementary Concept]
- DMB220 [MeSH Supplementary Concept]
- HP 977 [MeSH Supplementary Concept]
- HZ1006 [MeSH Supplementary Concept]
- IC 202A [MeSH Supplementary Concept]
- IC 202B [MeSH Supplementary Concept]
- IC 202C [MeSH Supplementary Concept]
- IK 682 [MeSH Supplementary Concept]
- IKH 12 [MeSH Supplementary Concept]
- KA1010 [MeSH Supplementary Concept]
- KBH A42 [MeSH Supplementary Concept]
- KIN-841 [MeSH Supplementary Concept]
- LAQ824 [MeSH Supplementary Concept]
- LPC-011 [MeSH Supplementary Concept]
- MC1568 [MeSH Supplementary Concept]
- MC1575 [MeSH Supplementary Concept]
- MC1742 [MeSH Supplementary Concept]
- MC2625 [MeSH Supplementary Concept]
- OSU8 1 [MeSH Supplementary Concept]
- P 10294 [MeSH Supplementary Concept]
- RG 6866 [MeSH Supplementary Concept]
- S 29606 [MeSH Supplementary Concept]
- S 30621 [MeSH Supplementary Concept]
- SC 903 [MeSH Supplementary Concept]
- SE 205 [MeSH Supplementary Concept]
- TAPI-2 [MeSH Supplementary Concept]
- U 27391 [MeSH Supplementary Concept]
- VRC3375 [MeSH Supplementary Concept]
- WMJ-8-B [MeSH Supplementary Concept]
- WT161 [MeSH Supplementary Concept]
- Y 41654 [MeSH Supplementary Concept]
- enactin [MeSH Supplementary Concept]
- fusigen [MeSH Supplementary Concept]
- tubacin [MeSH Supplementary Concept]
- zincov [MeSH Supplementary Concept]
- Semantic type(s)
- UMLS correspondences (same concept)
A class of weak acids with the general formula R-CONHOH.
https://antadir.com/wp-content/uploads/2022/12/FS-AAH-10-22.pdf
2022
false
false
false
France
scientific and technical information
disabled persons
family allowances
Adult
acetohydroxamic acid
acetohydroxamic acid
Handicap
Handicap
socialism
adulthood
Disability
adult
Adult
handicap
aid to families with dependent children
hydroxamic acids
---
https://antadir.com/wp-content/uploads/2022/08/FS-MVA-Compl%C2%82mentAAH-06-21.pdf
2021
false
false
false
France
scientific and technical information
independent living
acetohydroxamic acid
Complement
acetohydroxamic acid
socialism
hydroxamic acids
---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1209
2018
false
false
false
Canada
French
journal article
treatment outcome
disease-free survival
carfilzomib
elotuzumab
daratumumab
antineoplastic agents
antineoplastic agents
ixazomib
recurrence
multiple myeloma
oligopeptides
antibodies, monoclonal, humanized
antibodies, monoclonal
boron compounds
glycine
glycine
indoles
hydroxamic acids
Panobinostat
---
http://www.has-sante.fr/portail/jcms/c_2628641/fr/farydak
2016
false
false
false
France
French
treatment outcome
orphan drug production
panobinostat
antineoplastic agents
antineoplastic combined chemotherapy protocols
dexamethasone
adult
administration, oral
multiple myeloma
Refractory Multiple Myeloma
Recurrent Multiple Myeloma
histone deacetylase inhibitors
aged
Bortezomib
evaluation of the transparency committee
insurance, health, reimbursement
indoles
hydroxamic acids
Panobinostat
---
https://www.ema.europa.eu/medicines/human/EPAR/Farydak
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
panobinostat
drug approval
europe
drug monitoring
product surveillance, postmarketing
antineoplastic agents
antineoplastic agents
antineoplastic combined chemotherapy protocols
dexamethasone
adult
administration, oral
multiple myeloma
Progression of Multiple Myeloma or Plasma Cell Leukemia
Refractory Multiple Myeloma
Recurrent Multiple Myeloma
histone deacetylase inhibitors
histone deacetylase inhibitors
pregnancy
breast feeding
aged
drug interactions
survival analysis
drug evaluation, preclinical
Bortezomib
indoles
hydroxamic acids
indoles
hydroxamic acids
Panobinostat
Panobinostat
---